Liposomes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global liposomes market is set to witness impressive growth, with market valuations projected to increase from $7.4 billion in 2024 to an anticipated $10.67 billion by 2031. This represents a robust CAGR of 5.2%, fueled by advancements in drug delivery technologies and the rising incidence of chronic diseases.
Innovations in Liposomal Drug Delivery Systems
Technological advancements in liposomal drug delivery systems are revolutionizing the pharmaceutical landscape. Known for their small size, biocompatibility, and chemical stability, liposomes have become integral to the field of nanomedicine. Their ability to enhance the functionality of active pharmaceutical ingredients—such as prolonging shelf life and improving drug formulations—has positioned them as a preferred method for drug delivery.
The development of liposomal formulations for topical use in treating skin conditions and other medical applications highlights the increasing significance of liposome-based technologies. As technology continues to evolve, liposomal nanotechnology is poised to become a more reliable manufacturing platform, particularly in public health and medical diagnostics.
Rising Demand for Liposomal Drugs
The demand for liposomal drugs is escalating, driven by the increasing prevalence of chronic diseases, cancer, and lifestyle-related conditions such as diabetes and obesity. Liposomal drugs offer a promising solution for treating serious diseases due to their targeted delivery mechanisms and reduced side effects.
In developing countries like India, Mexico, and Brazil, the growing patient population and increased awareness of health and wellness present significant market opportunities. The rising disposable income and economic development in these emerging markets further support the long-term growth of the liposomes market.
Improving Healthcare Infrastructure
The strengthening of healthcare infrastructure and increased government healthcare expenditure in both developed and developing countries are key factors driving market growth. Enhanced healthcare infrastructure facilitates better access to advanced therapeutics, thereby boosting the demand for liposomal drugs.
In countries such as the United States, the high prevalence of chronic diseases, strong healthcare infrastructure, and presence of leading market players are contributing to market growth. For instance, the American Cancer Society's 2022 report highlighted over 1.9 million new cases of cancer and more than 609,360 cancer-related deaths, underscoring the need for advanced therapeutics.
Growing Market in Germany
Germany's rigorous research and development activities in lipid pharmaceuticals, particularly for cardiovascular diseases (CVDs), are expected to further drive the liposomes market. With cardiovascular disorders being the leading cause of death in Germany—accounting for over 40% of all deaths—the development of innovative liposomal medications is crucial for reducing the prevalence and associated healthcare costs of CVDs.
Emerging Market in China
China is emerging as a key market for liposomes, driven by the rising prevalence of chronic diseases, an increasing elderly population, and market penetration by international players. The country's large patient pool and demand for innovative medications, such as liposomal drugs, present significant growth opportunities.
Dominant Distribution Channels
Pharmacies are a critical segment in the distribution of liposomal drugs, holding approximately 90.2% of the total market share in 2022. The high prevalence of chronic and skin diseases drives the demand for liposomal drugs for therapeutic purposes. According to WHO estimates, non-communicable diseases (NCDs) account for 41 million deaths each year, with cardiovascular diseases and cancers being the leading causes.
Competitive Landscape
Leading players in the liposomes market are employing various strategies, including collaborations and the introduction of new products. Notable developments include:
• In January 2022, Pfizer Inc. and Acuitas Therapeutics signed a development and opportunity agreement, enabling Pfizer to develop vaccines using Acuitas' lipid nanoparticle (LNP) technology.
• In October 2021, Evonik introduced a new version of LIPEX® liposome extruders. LIPEX® Flow offers an improved solution for drug designers and manufacturers, facilitating the market introduction of liposomal pharmaceuticals.
The global liposomes market is poised to witness substantial growth in the coming years, driven by technological advancements, increasing demand for advanced therapeutics, and strategic collaborations among key players.
Key Market Players Include
• Novartis AG (Liposoma BV)
• Precision NanoSystems Inc
• Janssen Pharmaceutical Companies (Johnson & Johnson)
• Encapsula Nano Sciences
• Synpac-Kingdom Pharmaceutical Co., Ltd
• Celsion GmbH
• Gilead Sciences, Inc
• Pacira BioSciences, Inc.
• Luye Pharma Group
• Sun Pharma Industries Ltd
• Shanghai New Asia Pharmaceutical Co., Ltd.
• ENERGY DELIVERY SOLUTIONs
• Creative Biolabs
• Nanovex Biotechnologies SL
• Insys Therapeutics Inc
• Fujifilm Holdings Corporation
• Virpax Pharmaceuticals
• Azaya Therapeutics
• Avanti Polar Lipids, Inc.
• Breath Therapeutics (Zambon company)
• Getwell
• Taiwan Liposome Company Ltd
• Fresenius Health Care Group
• Xellia Pharmaceuticals (Novo Holdings A/S)
• Jazz Pharmaceuticals plc
• Ipsen Biopharmaceuticals, Inc.
• Baxter
• GMPriority Pharma
• S. G. Biopharm Pvt. Ltd
Global Liposomes market is Segmented as Below:
By Product:
• Simple Liposomes
• Formulated Liposomes
o Doxorubicin Liposomes
o Amphotericin B Liposomes
o Paclitaxel Liposomes
o Cytarabine Liposomes
o Irinotecan Liposomes
o Cisplatin Liposomes
o Others
• Vaccines
By Application:
• Drug delivery
o Cancer
o Fungal Infection
o Viral & Parasite Infection
o Others
• Gene Delivery/Transfection
• Contrast agents for medical imaging
• Model Cell Membranes
By Distribution Channel:
• Retail Sales
o Academic & Research Laboratories
o Biopharmaceutical Companies
o Clinical Research Organizations
o Others
• Distributional Sales
o Hospital Pharmacies
o Retail Pharmacies
o Mail Order Pharmacies
o Drug Stores
By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa
Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.
- 1. Executive Summary
- 1.1. Global Liposomes Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2023
- 1.5. Analyst Recommendations
- 2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. Porter’s Five Forces Analysis
- 2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
- 2.6. Impact of Ukraine-Russia Conflict
- 2.7. Economic Overview
- 2.7.1. World Economic Projections
- 2.8. PESTLE Analysis
- 3. Global Liposomes Market Outlook, 2018 – 2031
- 3.1. Global Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
- 3.1.1. Key Highlights
- 3.1.1.1. Simple Liposomes
- 3.1.1.2. Formulated Liposomes
- 3.1.1.2.1. Doxorubicin Liposomes
- 3.1.1.2.2. Amphotericin B Liposomes
- 3.1.1.2.3. Paclitaxel Liposomes
- 3.1.1.2.4. Cytarabine Liposomes
- 3.1.1.2.5. Irinotecan Liposomes
- 3.1.1.2.6. Cisplatin Liposomes
- 3.1.1.2.7. Others
- 3.1.1.3. Vaccines
- 3.2. Global Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
- 3.2.1. Key Highlights
- 3.2.1.1. Drug delivery
- 3.2.1.1.1. Cancer
- 3.2.1.1.2. Fungal Infection
- 3.2.1.1.3. Viral & Parasite Infection
- 3.2.1.1.4. Others
- 3.2.1.2. Gene Delivery/Transfection
- 3.2.1.3. Contrast agents for medical imaging
- 3.2.1.4. Model Cell Membranes
- 3.3. Global Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
- 3.3.1.1. Retail Sales
- 3.3.1.1.1. Academic & Research Laboratories
- 3.3.1.1.2. Biopharmaceutical Companies
- 3.3.1.1.3. Clinical Research Organizations
- 3.3.1.1.4. Others
- 3.3.1.2. Distributional Sales
- 3.3.1.2.1. Hospital Pharmacies
- 3.3.1.2.2. Retail Pharmacies
- 3.3.1.2.3. Mail Order Pharmacies
- 3.3.1.2.4. Drug Stores
- 3.4. Global Liposomes Market Outlook, by Region, Value (US$ Bn), 2018 – 2031
- 3.4.1. Key Highlights
- 3.4.1.1. North America
- 3.4.1.2. Europe
- 3.4.1.3. Asia Pacific
- 3.4.1.4. Latin America
- 3.4.1.5. Middle East & Africa
- 4. North America Liposomes Market Outlook, 2018 – 2031
- 4.1. North America Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
- 4.1.1.1. Simple Liposomes
- 4.1.1.2. Formulated Liposomes
- 4.1.1.2.1. Doxorubicin Liposomes
- 4.1.1.2.2. Amphotericin B Liposomes
- 4.1.1.2.3. Paclitaxel Liposomes
- 4.1.1.2.4. Cytarabine Liposomes
- 4.1.1.2.5. Irinotecan Liposomes
- 4.1.1.2.6. Cisplatin Liposomes
- 4.1.1.2.7. Others
- 4.1.1.3. Vaccines
- 4.2. North America Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
- 4.2.1.1. Drug delivery
- 4.2.1.1.1. Cancer
- 4.2.1.1.2. Fungal Infection
- 4.2.1.1.3. Viral & Parasite Infection
- 4.2.1.1.4. Others
- 4.2.1.2. Gene Delivery/Transfection
- 4.2.1.3. Contrast agents for medical imaging
- 4.2.1.4. Model Cell Membranes
- 4.3. North America Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 4.3.1. Key Highlights
- 4.3.1.1. Retail Sales
- 4.3.1.1.1. Academic & Research Laboratories
- 4.3.1.1.2. Biopharmaceutical Companies
- 4.3.1.1.3. Clinical Research Organizations
- 4.3.1.1.4. Others
- 4.3.1.2. Distributional Sales
- 4.3.1.2.1. Hospital Pharmacies
- 4.3.1.2.2. Retail Pharmacies
- 4.3.1.2.3. Mail Order Pharmacies
- 4.3.1.2.4. Drug Stores
- 4.4. North America Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
- 4.4.1.1. U.S. Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 4.4.1.2. U.S. Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 4.4.1.3. U.S. Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.4.1.4. Canada Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 4.4.1.5. Canada Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 4.4.1.6. Canada Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis
- 5. Europe Liposomes Market Outlook, 2018 – 2031
- 5.1. Europe Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
- 5.1.1. Key Highlights
- 5.1.1.1. Simple Liposomes
- 5.1.1.2. Formulated Liposomes
- 5.1.1.2.1. Doxorubicin Liposomes
- 5.1.1.2.2. Amphotericin B Liposomes
- 5.1.1.2.3. Paclitaxel Liposomes
- 5.1.1.2.4. Cytarabine Liposomes
- 5.1.1.2.5. Irinotecan Liposomes
- 5.1.1.2.6. Cisplatin Liposomes
- 5.1.1.2.7. Others
- 5.1.1.3. Vaccines
- 5.2. Europe Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
- 5.2.1. Key Highlights
- 5.2.1.1. Drug delivery
- 5.2.1.1.1. Cancer
- 5.2.1.1.2. Fungal Infection
- 5.2.1.1.3. Viral & Parasite Infection
- 5.2.1.1.4. Others
- 5.2.1.2. Gene Delivery/Transfection
- 5.2.1.3. Contrast agents for medical imaging
- 5.2.1.4. Model Cell Membranes
- 5.3. Europe Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
- 5.3.1.1. Retail Sales
- 5.3.1.1.1. Academic & Research Laboratories
- 5.3.1.1.2. Biopharmaceutical Companies
- 5.3.1.1.3. Clinical Research Organizations
- 5.3.1.1.4. Others
- 5.3.1.2. Distributional Sales
- 5.3.1.2.1. Hospital Pharmacies
- 5.3.1.2.2. Retail Pharmacies
- 5.3.1.2.3. Mail Order Pharmacies
- 5.3.1.2.4. Drug Stores
- 5.4. Europe Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 5.4.1. Key Highlights
- 5.4.1.1. Germany Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 5.4.1.2. Germany Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
- 5.4.1.3. Germany Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.1.4. U.K. Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 5.4.1.5. U.K. Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 5.4.1.6. U.K. Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.4.1.7. France Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 5.4.1.8. France Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 5.4.1.9. France Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.1.10. Italy Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 5.4.1.11. Italy Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 5.4.1.12. Italy Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.1.13. Turkey Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 5.4.1.14. Turkey Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
- 5.4.1.15. Turkey Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.1.16. Russia Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 5.4.1.17. Russia Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
- 5.4.1.18. Russia Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.1.19. Rest of Europe Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
- 5.4.1.20. Rest of Europe Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 5.4.1.21. Rest of Europe Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis
- 6. Asia Pacific Liposomes Market Outlook, 2018 – 2031
- 6.1. Asia Pacific Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
- 6.1.1. Key Highlights
- 6.1.1.1. Simple Liposomes
- 6.1.1.2. Formulated Liposomes
- 6.1.1.2.1. Doxorubicin Liposomes
- 6.1.1.2.2. Amphotericin B Liposomes
- 6.1.1.2.3. Paclitaxel Liposomes
- 6.1.1.2.4. Cytarabine Liposomes
- 6.1.1.2.5. Irinotecan Liposomes
- 6.1.1.2.6. Cisplatin Liposomes
- 6.1.1.2.7. Others
- 6.1.1.3. Vaccines
- 6.2. Asia Pacific Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
- 6.2.1.1. Drug delivery
- 6.2.1.1.1. Cancer
- 6.2.1.1.2. Fungal Infection
- 6.2.1.1.3. Viral & Parasite Infection
- 6.2.1.1.4. Others
- 6.2.1.2. Gene Delivery/Transfection
- 6.2.1.3. Contrast agents for medical imaging
- 6.2.1.4. Model Cell Membranes
- 6.3. Asia Pacific Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.3.1. Key Highlights
- 6.3.1.1. Retail Sales
- 6.3.1.1.1. Academic & Research Laboratories
- 6.3.1.1.2. Biopharmaceutical Companies
- 6.3.1.1.3. Clinical Research Organizations
- 6.3.1.1.4. Others
- 6.3.1.2. Distributional Sales
- 6.3.1.2.1. Hospital Pharmacies
- 6.3.1.2.2. Retail Pharmacies
- 6.3.1.2.3. Mail Order Pharmacies
- 6.3.1.2.4. Drug Stores
- 6.3.2. BPS Analysis/Market Attractiveness Analysis
- 6.4. Asia Pacific Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 6.4.1. Key Highlights
- 6.4.1.1. China Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 6.4.1.2. China Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 6.4.1.3. China Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.4.1.4. Japan Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 6.4.1.5. Japan Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 6.4.1.6. Japan Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.4.1.7. South Korea Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
- 6.4.1.8. South Korea Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
- 6.4.1.9. South Korea Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.4.1.10. India Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 6.4.1.11. India Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 6.4.1.12. India Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.4.1.13. Southeast Asia Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
- 6.4.1.14. Southeast Asia Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 6.4.1.15. Southeast Asia Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.4.1.16. Rest of Asia Pacific Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 6.4.1.17. Rest of Asia Pacific Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 6.4.1.18. Rest of Asia Pacific Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis
- 7. Latin America Liposomes Market Outlook, 2018 – 2031
- 7.1. Latin America Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
- 7.1.1.1. Simple Liposomes
- 7.1.1.2. Formulated Liposomes
- 7.1.1.2.1. Doxorubicin Liposomes
- 7.1.1.2.2. Amphotericin B Liposomes
- 7.1.1.2.3. Paclitaxel Liposomes
- 7.1.1.2.4. Cytarabine Liposomes
- 7.1.1.2.5. Irinotecan Liposomes
- 7.1.1.2.6. Cisplatin Liposomes
- 7.1.1.2.7. Others
- 7.1.1.3. Vaccines
- 7.2. Latin America Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
- 7.2.1.1. Drug delivery
- 7.2.1.1.1. Cancer
- 7.2.1.1.2. Fungal Infection
- 7.2.1.1.3. Viral & Parasite Infection
- 7.2.1.1.4. Others
- 7.2.1.2. Gene Delivery/Transfection
- 7.2.1.3. Contrast agents for medical imaging
- 7.2.1.4. Model Cell Membranes
- 7.3. Latin America Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.3.1. Key Highlights
- 7.3.1.1. Retail Sales
- 7.3.1.1.1. Academic & Research Laboratories
- 7.3.1.1.2. Biopharmaceutical Companies
- 7.3.1.1.3. Clinical Research Organizations
- 7.3.1.1.4. Others
- 7.3.1.2. Distributional Sales
- 7.3.1.2.1. Hospital Pharmacies
- 7.3.1.2.2. Retail Pharmacies
- 7.3.1.2.3. Mail Order Pharmacies
- 7.3.1.2.4. Drug Stores
- 7.3.2. BPS Analysis/Market Attractiveness Analysis
- 7.4. Latin America Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
- 7.4.1.1. Brazil Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 7.4.1.2. Brazil Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 7.4.1.3. Brazil Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.4.1.4. Mexico Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 7.4.1.5. Mexico Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 7.4.1.6. Mexico Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.4.1.7. Argentina Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 7.4.1.8. Argentina Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
- 7.4.1.9. Argentina Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.4.1.10. Rest of Latin America Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 7.4.1.11. Rest of Latin America Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 7.4.1.12. Rest of Latin America Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis
- 8. Middle East & Africa Liposomes Market Outlook, 2018 – 2031
- 8.1. Middle East & Africa Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
- 8.1.1. Key Highlights
- 8.1.1.1. Simple Liposomes
- 8.1.1.2. Formulated Liposomes
- 8.1.1.2.1. Doxorubicin Liposomes
- 8.1.1.2.2. Amphotericin B Liposomes
- 8.1.1.2.3. Paclitaxel Liposomes
- 8.1.1.2.4. Cytarabine Liposomes
- 8.1.1.2.5. Irinotecan Liposomes
- 8.1.1.2.6. Cisplatin Liposomes
- 8.1.1.2.7. Others
- 8.1.1.3. Vaccines
- 8.2. Middle East & Africa Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
- 8.2.1. Key Highlights
- 8.2.1.1. Drug delivery
- 8.2.1.1.1. Cancer
- 8.2.1.1.2. Fungal Infection
- 8.2.1.1.3. Viral & Parasite Infection
- 8.2.1.1.4. Others
- 8.2.1.2. Gene Delivery/Transfection
- 8.2.1.3. Contrast agents for medical imaging
- 8.2.1.4. Model Cell Membranes
- 8.3. Middle East & Africa Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.3.1. Key Highlights
- 8.3.1.1. Retail Sales
- 8.3.1.1.1. Academic & Research Laboratories
- 8.3.1.1.2. Biopharmaceutical Companies
- 8.3.1.1.3. Clinical Research Organizations
- 8.3.1.1.4. Others
- 8.3.1.2. Distributional Sales
- 8.3.1.2.1. Hospital Pharmacies
- 8.3.1.2.2. Retail Pharmacies
- 8.3.1.2.3. Mail Order Pharmacies
- 8.3.1.2.4. Drug Stores
- 8.3.2. BPS Analysis/Market Attractiveness Analysis
- 8.4. Middle East & Africa Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 8.4.1. Key Highlights
- 8.4.1.1. GCC Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 8.4.1.2. GCC Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 8.4.1.3. GCC Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.4.1.4. South Africa Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
- 8.4.1.5. South Africa Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
- 8.4.1.6. South Africa Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.4.1.7. Egypt Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 8.4.1.8. Egypt Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 8.4.1.9. Egypt Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.4.1.10. Nigeria Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 8.4.1.11. Nigeria Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
- 8.4.1.12. Nigeria Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.4.1.13. Rest of Middle East & Africa Liposomes Market by Product, Value (US$ Bn), 2018 – 2031
- 8.4.1.14. Rest of Middle East & Africa Liposomes Market by Application, Value (US$ Bn), 2018 – 2031
- 8.4.1.15. Rest of Middle East & Africa Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis
- 9. Competitive Landscape
- 9.1. By Product vs by Application Heat map
- 9.2. Company Market Share Analysis, 2023
- 9.3. Competitive Dashboard
- 9.4. Company Profiles
- 9.4.1. Novartis AG (Liposoma BV)
- 9.4.1.1. Company Overview
- 9.4.1.2. Product Portfolio
- 9.4.1.3. Financial Overview
- 9.4.1.4. Business Strategies and Development
- 9.4.2. Precision NanoSystems Inc
- 9.4.2.1. Company Overview
- 9.4.2.2. Product Portfolio
- 9.4.2.3. Financial Overview
- 9.4.2.4. Business Strategies and Development
- 9.4.3. Janssen Pharmaceutical Companies (Johnson & Johnson
- 9.4.3.1. Company Overview
- 9.4.3.2. Product Portfolio
- 9.4.3.3. Financial Overview
- 9.4.3.4. Business Strategies and Development
- 9.4.4. Encapsula Nano Sciences
- 9.4.4.1. Company Overview
- 9.4.4.2. Product Portfolio
- 9.4.4.3. Financial Overview
- 9.4.4.4. Business Strategies and Development
- 9.4.5. Synpac-Kingdom Pharmaceutical Co., Ltd
- 9.4.5.1. Company Overview
- 9.4.5.2. Product Portfolio
- 9.4.5.3. Financial Overview
- 9.4.5.4. Business Strategies and Development
- 9.4.6. Celsion GmbH
- 9.4.6.1. Company Overview
- 9.4.6.2. Product Portfolio
- 9.4.6.3. Financial Overview
- 9.4.6.4. Business Strategies and Development
- 9.4.7. Gilead Sciences, Inc
- 9.4.7.1. Company Overview
- 9.4.7.2. Product Portfolio
- 9.4.7.3. Financial Overview
- 9.4.7.4. Business Strategies and Development
- 9.4.8. Pacira BioSciences, Inc.
- 9.4.8.1. Company Overview
- 9.4.8.2. Product Portfolio
- 9.4.8.3. Financial Overview
- 9.4.8.4. Business Strategies and Development
- 9.4.9. Luye Pharma Group
- 9.4.9.1. Company Overview
- 9.4.9.2. Product Portfolio
- 9.4.9.3. Financial Overview
- 9.4.9.4. Business Strategies and Development
- 9.4.10. Sun Pharma Industries Ltd
- 9.4.10.1. Company Overview
- 9.4.10.2. Product Portfolio
- 9.4.10.3. Financial Overview
- 9.4.10.4. Business Strategies and Development
- 10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook